One year in review 2016: Sjögren's syndrome.
Sjögren's syndrome (SS) is a complex heterogeneous disease charactered by a broad spectrum of clinical and serological manifestations, including non-Hodgkin's lymphoma (NHL). Last year, 2015, was an exciting year for research into SS with novel insights into disease pathogenesis, clinical aspects and long-term outcomes. In addition, the use of biologic therapy in SS is rapidly expanding, with new evidence emerging regarding potential therapeutic targets. In this article, we will provide an overview of the recent literature on the pathogenesis, clinical features and novel treatments of SS.
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Francesco
F
Ferro
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Roberta
R
Vagelli
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Italy.
Cosimo
C
Bruni
Rheumatology Unit, University of Perugia, Italy.
Giacomo
G
Cafaro
Rheumatology Unit, University of Perugia, Italy.
Elisa
E
Marcucci
Rheumatology Unit, University of Perugia, Italy.
Elena
E
Bartoloni
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com.
Chiara
C
Baldini
D015415:Biomarkers; D006801:Humans; D008223:Lymphoma / Q000209:etiology; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*
D015415:Biomarkers